Rachel N. Grisham, MD, on Avutometinib Plus Defactinib in Low-Grade Serous Ovarian Cancer

Posted: Tuesday, April 8, 2025

Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, provides an overview of the MEK inhibitor avutometinib and the FAK inhibitor defactinib. She discusses the findings of the RAMP 201 trial, which looked at the efficacy of avutometinib and defactinib in low-grade serous ovarian cancer, as well as a brief update on the RAMP 301 trial, which is comparing the combination with standard treatments. She also shares her thoughts on the future role of such dual-targeted therapy for this type of ovarian cancer.